- Home
- SEZL vs PHAT Comparison
SEZL vs PHAT Comparison
Compare SEZL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- PHAT
- Stock Information
- Founded
- SEZL 2016
- PHAT 2018
- Country
- SEZL United States
- PHAT United States
- Employees
- SEZL N/A
- PHAT N/A
- Industry
- SEZL Diversified Financial Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- PHAT Health Care
- Exchange
- SEZL Nasdaq
- PHAT Nasdaq
- Market Cap
- SEZL 1.2B
- PHAT 1.2B
- IPO Year
- SEZL N/A
- PHAT 2019
- Fundamental
- Price
- SEZL $385.00
- PHAT $8.78
- Analyst Decision
- SEZL Strong Buy
- PHAT Strong Buy
- Analyst Count
- SEZL 2
- PHAT 4
- Target Price
- SEZL $231.50
- PHAT $22.50
- AVG Volume (30 Days)
- SEZL 134.2K
- PHAT 1.9M
- Earning Date
- SEZL 11-07-2024
- PHAT 11-07-2024
- Dividend Yield
- SEZL N/A
- PHAT N/A
- EPS Growth
- SEZL 1005.78
- PHAT N/A
- EPS
- SEZL 9.51
- PHAT N/A
- Revenue
- SEZL $221,806,305.00
- PHAT $26,270,000.00
- Revenue This Year
- SEZL $49.16
- PHAT $6,714.96
- Revenue Next Year
- SEZL $31.93
- PHAT $293.69
- P/E Ratio
- SEZL $40.50
- PHAT N/A
- Revenue Growth
- SEZL 49.13
- PHAT N/A
- 52 Week Low
- SEZL $9.75
- PHAT $6.07
- 52 Week High
- SEZL $454.16
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SEZL 70.53
- PHAT 23.73
- Support Level
- SEZL $345.21
- PHAT $8.91
- Resistance Level
- SEZL $414.93
- PHAT $19.05
- Average True Range (ATR)
- SEZL 40.98
- PHAT 1.74
- MACD
- SEZL 14.06
- PHAT -1.05
- Stochastic Oscillator
- SEZL 73.62
- PHAT 2.19
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.